N
FATE icon

Natixis’s Fate Therapeutics FATE Stock Holding History

Natixis’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,703
Closed -$15.4K – 1061
2023
Q1 		$15.4K Sell
2,703
-168
-6% -$1.01K ﹤0.01% 876
2022
Q4 		$29K Buy
+2,871
New +$53.9K ﹤0.01% 961
2021
Q3 		– Sell
-2,891
Closed -$251K – 1225
2021
Q2 		$251K Buy
+2,891
New +$233K ﹤0.01% 798

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Natixis's FATE Position: Q2 2023 in Review

Natixis sold out of Fate Therapeutics (FATE) in Q2 2023, closing a stake of 2,703 shares — an estimated $15.4K sold.

Natixis first reported a position in FATE in Q2 2021 and held it in 3 quarters. The position peaked at $251K in Q2 2021. 188 funds tracked by Wall St. Rank hold FATE as of Q2 2023.

  • Natixis reported no remaining Fate Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Natixis sold 2,703 Fate Therapeutics shares in Q2 2023, an estimated $15.4K.
  • Natixis first reported a position in Fate Therapeutics in Q2 2021 and held it in 3 quarters.
  • Natixis's Fate Therapeutics position peaked at $251K in Q2 2021.
  • 188 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2023.

Based on Natixis's 13F filing for Q2 2023, filed 11 Aug 2023.